Should I Buy LFMD? LFMD 2026 Analysis

Should You Buy LifeMD Inc (LFMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.140

1 Day change

13.36%

52 Week Range

15.840

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: the trend is still decisively bearish and near-term pattern stats skew negative (next month expected drift lower).
Although LFMD is extremely oversold (RSI_6 ~16.8) and could bounce, there’s no proprietary timing signal today and momentum (MACD) is still deteriorating—risk of catching a falling knife is high.
Wall Street remains broadly constructive (Buy/Overweight ratings intact), but repeated price-target cuts and guidance-related pressure suggest upside is more “2026 thesis” than “buy-it-today” setup.

Technical Analysis

Trend/Momentum: Bearish structure with SMA_200 > SMA_20 > SMA_5; MACD histogram (-0.0518) is below zero and negatively expanding → downtrend still strengthening.
Mean-reversion setup: RSI_6 at 16.787 signals extreme oversold; a short-term dead-cat bounce is possible, but not confirmed.
Levels: Price 3.02 is sitting near S1 (3.07) and above S2 (2.885). A break below ~2.89 would be another technical breakdown; upside resistance begins around Pivot 3.37 then R1 3.67.
Pattern-based forward look: Similar-pattern model indicates ~60% probability of further weakness (approx. -1.89% next day, -0.55% next week, -5.37% next month).
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Very low OI put/call (0.12) implies call-heavy open interest (bullish positioning/skew).
Flow today: Put/call by volume at 0.66 suggests calls still leading, but not an extreme “risk-on” chase.
Volatility: IV_30d ~97.5% vs HV ~89.4%, with IV percentile ~82% → options are expensive; market is pricing large moves (often seen around uncertainty/downtrends).
Activity: Today’s volume (573) is far below 5D/10D averages (3290/2259), so today’s flow is not a strong conviction read.

Technical Summary

Sell

Buy

Positive Catalysts

- Analyst theses still point to 2026 re-acceleration drivers (e.g., improving GLP-1 pricing dynamics, stricter enforcement vs compounders, potential oral Wegovy timing cited by analysts).
- Revenue is still growing (+12.95% YoY in 2025/Q3), indicating demand is not collapsing.
- Call-heavy options open interest (very low put/call OI) suggests investors are positioned for upside over time.

Neutral/Negative Catalysts

- Technical downtrend remains intact (bearish moving averages + weakening MACD), increasing probability of continued drawdown before any durable bottom.
- Competitive pressure in weight management (low-cost compounded GLP-1 offerings) has been significant enough to drive misses and guidance resets (per analyst commentary).
- No fresh news catalysts in the past week to trigger an immediate narrative reversal.
- Near-term statistical pattern read points to continued downside bias over 1D/1W/1M horizons.

Financial Performance

Latest quarter: 2025/Q3.
Growth: Revenue 60.17M, up 12.95% YoY (top-line still expanding).
Profitability: Net income -4.58M (down -15.67% YoY) and EPS -0.10 (down -23.08% YoY) → losses widened.
Margins: Gross margin 87.69%, down ~3.20% YoY → some margin compression alongside competitive pressure.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Street stance: Predominantly Buy/Overweight maintained across firms, but sentiment has cooled via sharp price-target cuts after Q3 miss/guidance updates.
Recent changes (Nov 2025):
- H.C. Wainwright: PT cut 13 → 9, Buy maintained.
- KeyBanc: PT cut 12 → 8, Overweight maintained.
- B. Riley: PT cut 12 → 10, Buy maintained.
- Lake Street: PT cut 14 → 8, Buy maintained.
- BTIG: PT cut 18 → 10, Buy maintained.
Wall Street pros: Belief that current GLP-1/compounding headwinds are temporary and that 2026 product/market shifts can re-accelerate growth.
Wall Street cons: Near-term execution/guidance risk remains elevated; competitive pricing pressure is real now, which is why targets were cut aggressively.

7 Analyst Rating

Wall Street analysts forecast LFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFMD is 9.67 USD with a low forecast of 6 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 2.770

Low

Averages

9.67

High

Current: 2.770

Low

Averages

9.67

High

H.C. Wainwright

Yi Chen

Buy

downgrade

$13 -> $9

AI Analysis

2025-11-19

Reason

H.C. Wainwright

Yi Chen

Price Target

$13 -> $9

AI Analysis

2025-11-19

downgrade

Buy

Reason

H.C. Wainwright analyst Yi Chen lowered the firm's price target on LifeMD to $9 from $13 and keeps a Buy rating on the shares following a top- and bottom-line miss in Q3. LifeMD, which is now a pure-play telehealth and pharmacy platform after the company divested its majority ownership in WorkSimpli, updated its 2025 total revenue guidance and the firm adjusted its projections accordingly, the analyst noted.

KeyBanc

Scott Schoenhaus

Overweight

downgrade

$12 -> $8

2025-11-19

Reason

KeyBanc

Scott Schoenhaus

Price Target

$12 -> $8

2025-11-19

downgrade

Overweight

Reason

KeyBanc analyst Scott Schoenhaus lowered the firm's price target on LifeMD (LFMD) to $8 from $12 and keeps an Overweight rating on the shares. The firm notes LifeMD is being impacted by low-cost compounders despite the FDA outlawing the practice earlier this year. However, KeyBanc expects cash prices for brand-name GLP-1s to continue to come down as well as stricter enforcement against compounders in FY26, which should benefit LifeMD due to its partnerships with Eli Lilly (LLY) and Novo (NVO). The firm also expects the launch of oral Wegovy in early FY26 to drive higher weight management subscribers.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LFMD

Unlock Now

LFMD Should I Buy

LFMD Should I Buy

Should You Buy LifeMD Inc (LFMD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch